David A Candito, Vladimir Simov, Anmol Gulati, Solomon Kattar, Ryan W Chau, Blair T Lapointe, Joey L Methot, Duane E DeMong, Thomas H Graham, Ravi Kurukulasuriya, Mitchell H Keylor, Ling Tong, Gregori J Morriello, John J Acton, Barbara Pio, Weiguo Liu, Jack D Scott, Michael J Ardolino, Theodore A Martinot, Matthew L Maddess, Xin Yan, Hakan Gunaydin, Rachel L Palte, Spencer E McMinn, Lisa Nogle, Hongshi Yu, Ellen C Minnihan, Charles A Lesburg, Ping Liu, Jing Su, Laxminarayan G Hegde, Lily Y Moy, Janice D Woodhouse, Robert Faltus, Tina Xiong, Paul Ciaccio, Jennifer A Piesvaux, Karin M Otte, Matthew E Kennedy, David Jonathan Bennett, Erin F DiMauro, Matthew J Fell, Santhosh Neelamkavil, Harold B Wood, Peter H Fuller, J Michael Ellis
Inhibition of leucine-rich repeat kinase 2 (LRRK2) kinase activity represents a genetically supported, chemically tractable, and potentially disease-modifying mechanism to treat Parkinson's disease. Herein, we describe the optimization of a novel series of potent, selective, central nervous system (CNS)-penetrant 1-heteroaryl-1 H -indazole type I (ATP competitive) LRRK2 inhibitors. Type I ATP-competitive kinase physicochemical properties were integrated with CNS drug-like properties through a combination of structure-based drug design and parallel medicinal chemistry enabled by sp3 -sp2 cross-coupling technologies...
December 7, 2022: Journal of Medicinal Chemistry